Friday Satellite Symposia

A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Sheraton - Napoleon Ballroom AB

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on the role of chimeric antigen receptor (CAR) T-cell therapy in the management of multiple myeloma (MM). Four clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, each faculty member will provide a number of interesting cases of patients with MM receiving treatment with available and investigational CAR T-cell therapies for program development. RTP will select specific deidentified patients for discussion during the activity consistent with the defined educational objectives. To set the stage for discussion and debate, at the beginning of each of the 4 modules, one of the faculty members will present a case from his/her practice. Each case discussion will attempt to frame a handful of educational issues and allow the faculty to describe how they currently think through the current and potential future role of CAR T-cell therapy for patients with MM. Following the case-based discussion, a faculty member will deliver a presentation reviewing relevant scientific knowledge, available data sets and ongoing research studies related to the topics under review. Audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Sarah Larson, MD

Shambavi Richard, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Peter Voorhees, MD
Atrium Health Levine Cancer Institute
Charlotte,  NC, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond

This program is supported by Agios Pharmaceuticals, Inc.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Great Hall BC

This 90-minute live symposium offers a comprehensive program on the rapidly evolving therapeutic landscape for sickle cell disease (SCD), designed to increase knowledge and competence in novel treatments. Expert faculty will provide an overview of the current burden of SCD, and the evolving role of new and emerging therapies, for improving patient outcomes. Faculty will discuss the distinct mechanisms, efficacy, and safety outcomes of gene therapy, and address practical considerations for its use, including myeloablative conditioning, fertility preservation, and the required referral infrastructure. A dedicated session will focus on emerging pyruvate kinase (PK) activators, reviewing their mechanism of action, recent clinical trial data on reducing VOCs and anemia, and logistical considerations for equitable patient access and safe treatment sequencing. The symposium culminates with a rapid-fire session presenting several complex clinical scenarios. Attendees will be challenged in making crucial treatment decisions followed by expert feedback and rationale to foster greater confidence in matching patients to appropriate SCD therapies. 

Chair:

Sophie Lanzkron, MD
Thomas Jefferson University
Philadelphia,  PA, United States

Speakers:

Haydar Frangoul, MD
TriStar Centennial
Nashville,  TN, United States

Madhav Vissa, MD, MS
UCSF Benioff Children's Hospitals
Oakland,  CA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together

This program is supported by Alexion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Johnson and Johnson.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Hall C

In this 90-minute symposium, a panel of 3 clinicians with extensive experience managing patients with AL amyloidosis will bring learners up to date on best practices for diagnosing and treating this challenging hematologic condition. The symposium will consist of 3 main segments, each concluding with a brief panel discussion: 

Segment 1 will focus on amyloidosis pathophysiology and use of clinical symptoms, biomarkers, and evidence-based algorithms to facilitate timely detection and accurate staging.  

Segment 2 will examine patient-centered treatment planning and include an overview of therapy selection and sequencing, clinical trial data for current and emerging therapies, and effective strategies for educating patients and individualizing care. 

Segment 3 will examine how to optimize care workflows through appropriate application of practice guidelines, digital tools, and multidisciplinary communication; and will use patient cases to illustrate effective, efficient supportive-care strategies. 

The symposium will conclude with a summary of the key take-home points and a Q&A session between learners and faculty. 

Speakers:

Morie Gertz, MD
Mayo Clinic Alix School of Medicine
Rochester,  United States

Suzanne Lentzsch, MD, PhD
Columbia University
New York,  NY, United States

Pedro Vianna, MD
Brigham and Women’s Hospital
Boston,  MA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation

This program is supported by an independent educational grant from AstraZeneca.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Hilton - Grand Ballroom CD

Delivered by three leading ALL experts, this activity will combine real-time assessment of clinician practice patterns, focused expert presentations, and multi-perspective case discussions to reevaluate the role of T-cell engager (TCE) therapy across ALL treatment settings, including sequencing strategies for available and emerging bispecifics. The program will also define best practices for MRD and biomarker testing to help identify patients who may benefit from subsequent CD19-directed therapy or re-challenge, clarify the evidence supporting next-generation bispecifics with a focus on efficacy, safety, and use following prior TCE and/or CAR-T therapy, and provide practical guidance on integrating expanding off-the-shelf immunotherapy options into individualized treatment pathways.

Chair:

Nicola Goekbuget, MD
University Hospital
Frankfurt,  Germany

Speakers:

Ibrahim Aldoss, MD
City of Hope
Duarte,  United States

Bijal Shah, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa,  FL, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review - A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Genmab US Inc

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Sheraton - Napoleon Ballroom CD

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on the use of bispecific antibodies in the management of non-Hodgkin lymphoma (NHL). Four leading clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. To support the theme of the activity, leading up to the symposium, RTP will recruit 2 additional investigators who will participate in a one-on-one interview with Dr Neil Love during which they will present challenging cases from their practices of patients with NHL treated or considered for treatment with bispecific antibodies for which they sought out input or a second opinion from a colleague. Excerpts from each interview will be selected for presentation during the symposium in accordance with the defined educational objectives. The agenda for the event, which will be divided into 4 topic modules, will feature case-based discussions set up by the video excerpts followed by faculty led presentations reviewing recent data sets, current management approaches and ongoing trials. To promote audience engagement, audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Nancy L Bartlett, MD
Washington University School of Medicine in St Louis
St Louis,  United States

Chan Cheah, MD, PhD
The University of Western Australia
Perth,  Australia

Lorenzo Falchi, MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum

This program is supported by an educational grant from Genmab. This activity is provided by PRIME Education. There is no fee to participate.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - R02-R05

 CD20 × CD3 bispecific antibodies (bsAbs) are reshaping the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), while introducing new clinical and operational challenges. Clinicians must make informed decisions around patient selection, sequencing alongside CAR T-cell therapy and other novel agents, outpatient initiation, toxicity monitoring, and care coordination across settings. This interactive, case-based program is designed to close the gap between evidence and execution by translating the latest clinical data and guideline updates into practical, real-world strategies. Through real-time polling, clinical decision checkpoints, and faculty-led discussion, learners will apply evidence in context and refine their clinical approach. 

Using real-world cases in DLBCL and FL, participants will build skills in selecting and sequencing bsAbs, implementing step-up dosing and outpatient workflows, and anticipating and managing toxicities such as CRS, ICANS, cytopenias, and infections. With a focus on practical implementation, the program addresses common barriers including staffing, infrastructure, and referral processes. Additionally, faculty will introduce the NHL BsAb Navigator, a point-of-care tool to support consistent integration of bsAbs into practice. Attendees will leave with actionable frameworks and workflow solutions to enhance care coordination, improve efficiency, and expand access to these therapies.

Speakers:

Jennifer L. Crombie, MD
Dana Farber Cancer Institute
Boston,  MA, United States

Yasmin H Karimi, MD
University of Michigan
Ann Arbor,  MI, United States

Shelby Sullivan, PharmD
PRIME Education, LLC
New York,  NY, United States

Managing Company Contact

Eryn Litvinas , PRIME Education, LLC
Email: [email protected]

---

CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation

This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 208-210

Join Decera Clinical Education for an engaging Master Class symposium exploring the latest advancements in CAR T-cell therapy for relapsed/refractory (R/R) lymphomas. This dynamic event features expert-led small group discussions, real-world case challenges, and interactive polling to examine the role of CAR T-cell therapies across B-cell lymphoma subtypes. Gain practical insights into patient selection, referral pathways, and coordination of care, along with strategies to manage acute and chronic toxicities such as CRS and ICANS. Learn how to educate patients and caregivers, implement survivorship planning, and optimize long-term outcomes. The symposium also highlights next-generation CAR T-cell innovations, including off-the-shelf products and combination strategies. Engage directly with faculty during live Q&A sessions, apply knowledge through interactive cases, and leave equipped to enhance care for patients receiving CAR T-cell therapy.

Chair:

Michael R. Bishop, MD
University of Chicago
Chicago,  IL, United States

Speakers:

Jeremy Abramson, MD
Harvard Medical School
Cambridge,  MA, United States

Caron Jacobson, MD
Harvard Medical School
Cambridge,  MA, United States

Michael D. Jain, MD, PhD
Moffitt Cancer Center
Tampa,  FL, United States

Tanya Siddiqi, MD
City of Hope
Irvine,  CA, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies

This program is supported by AbbVie Inc.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - La Nouvelle A-B

Blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive hematologic malignancy in which diagnostic delay and treatment uncertainty remain common because features overlap with cutaneous lymphomas, acute leukemias, and other myeloid neoplasms. The therapeutic landscape is expanding rapidly, with the only approved CD123-directed cytotoxin, an investigational CD123-directed antibody-drug conjugate under FDA review, and additional bispecifics, CAR T-cell platforms, and combination regimens advancing through development. This case-based session pairs interactive case discussion with focused didactic data to enable clinicians to apply current diagnostic criteria, interpret evolving evidence across frontline and relapsed/refractory settings, manage capillary leak syndrome and class-specific toxicities, and coordinate multidisciplinary care that incorporates transplant evaluation and clinical trial access across academic and community practice.

Chair:

Naveen Pemmaraju, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Andrew A. Lane, MD, PhD
Dana-Farber Cancer Institute
Boston,  MA, United States

Gary J. Schiller, MD
David Geffen School of Medicine at UCLA
Los Angeles,  CA, United States

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies

This program is supported by AstraZeneca, BeOne Medicines, and Lilly. Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 243-245

This engaging symposium will explore how shared decision-making, patient priorities, and rapidly evolving evidence can guide more individualized treatment selection and sequencing for patients with CLL/SLL. Developed by Decera Clinical Education in partnership with the CLL Society, the session will address persistent gaps in patient engagement, biomarker testing, and the practical integration of established and emerging targeted therapies. Through evidence-based challenges, interactive polling, and expert discussion, the program will examine how clinicians can better align treatment choices with patient goals, disease biology, current guideline recommendations, and new clinical data. Key themes include improving communication around treatment options, applying biomarker and resistance testing, selecting among fixed-duration and continuous regimens, and evaluating the roles of covalent and noncovalent BTK inhibitors, BCL-2 inhibitor–based combinations, BTK degraders, and cellular therapy. The overall purpose is to translate current and emerging evidence into patient-centered strategies that support equitable, informed, and preference-sensitive CLL/SLL care across frontline and relapsed/refractory settings.

Chair:

Nitin Jain, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Brian Koffman, MD
CLL Society
Claremont,  United States

Meghan C. Thompson, MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Jennifer A. Woyach, MD
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making

This program is supported by Servier Pharmaceuticals, LLC.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 343-345

This symposium focuses on optimizing personalized treatment strategies in acute myeloid leukemia (AML) through effective integration of molecular testing and targeted therapies. As treatment options expand to include agents targeting IDH1, IDH2, and FLT3 mutations, clinicians must navigate increasingly complex decision-making processes, particularly for older patients or patients who are not candidates for intensive therapy. The purpose of the session is to equip clinicians with practical, evidence-based approaches to when and how to perform molecular testing, interpret results, and apply findings to individualized treatment selection. Emphasis will be placed on bridging gaps between guideline recommendations and real-world practice, especially in community settings where barriers to timely testing and interpretation may persist. The live format enables expert discussion, case-based learning, real-time polling, and faculty-audience interaction through a live Q&A, supporting active application of knowledge. By engaging the audience in clinical scenarios and decision-making exercises, the session aims to improve confidence, consistency, and competency in managing patients with molecularly defined AML.

Chair:

Richard Stone, MD

Speakers:

Uma Borate, MD, MSc
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Curtis Lachowiez, MD
OHSU Knight Cancer Institute
Portland,  United States

Managing Company Contact

Alison McMorrow , Paradigm Medical Communications, LLC
Email: [email protected]

---

Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care

This program is supported by the Roswell Park Alliance Foundation. Other support is currently pending.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 343-345

Rapid advances in immune-based therapies for multiple myeloma have created meaningful gaps in clinician knowledge, treatment decision making, and care coordination, particularly for patients with relapsed or refractory disease. This activity aims to improve evidence-based care, coordination across treatment settings and outcomes for patients with multiple myeloma

Chair:

Marco Davila, MD, PhD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY, United States

Managing Company Contact

Ashley Snowden , Roswell Park Comprehensive Cancer Center
Email: [email protected]

---

Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease

This program is supported by Blueprint Medicines, a Sanofi company. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 265-268

Join Decera Clinical Education for an interactive symposium focused on improving timely diagnosis, risk stratification, and patient-centered management of systemic mastocytosis across indolent and advanced disease. This engaging program will translate evolving diagnostic standards and therapeutic evidence into practical, clinic-ready workflows, with emphasis on applying ICC/WHO criteria, interpreting bone marrow findings, serum tryptase, KIT D816V testing, and immunophenotyping, and recognizing the multisystem manifestations of disease. Through a team-based trivia format, case-driven discussion, real-time polling, and expert roundtable dialogue, the session will address common barriers that contribute to delayed diagnosis, misclassification, and inconsistent care. Key themes include distinguishing indolent from advanced systemic mastocytosis, assessing symptom burden and organ involvement, preventing and managing anaphylaxis, and selecting appropriate supportive, cytoreductive, KIT-targeted, or investigational treatment strategies. The overall purpose is to equip clinicians with actionable approaches to align therapy with disease subtype, patient goals, safety considerations, and longitudinal quality-of-life needs while strengthening multidisciplinary coordination across the care continuum.

Chair:

Daniel J DeAngelo, MD, PhD
Harvard Medical School
Boston,  MA, United States

Speakers:

Brian Chernak, MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

James K. McCloskey, MD
HMH John Theurer Cancer Center Lymphoma Hackensack
Hackensack,  United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Medical Crossfire(R): Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies

This program is supported by Sanofi

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 393-396

The therapeutic landscape of newly diagnosed multiple myeloma has been transformed over the past several years, with anti-CD38 monoclonal antibody-based quadruplet regimens emerging as the guideline-preferred frontline standard for transplant-eligible patients and a growing option for selected non-transplant candidates. Emerging data on subcutaneous and on-body anti-CD38 delivery, response-adapted maintenance, and the integration of measurable residual disease as a treatment decision tool have introduced new complexity into individualized treatment planning. Frontline strategies involving CAR-T cell therapy, bispecific antibodies, antibody-drug conjugates, and cereblon E3 ligase modulators are advancing rapidly in pivotal trials. This satellite symposium employs a debate-style educational design that pairs focused didactic content with moderated panel discussions, allowing four expert clinicians to examine evolving evidence and articulate differing perspectives on quadruplet therapy selection, MRD-guided treatment decisions, and the management of treatment-related adverse events across transplant-eligible and -ineligible populations. Attendees will leave better prepared to apply current evidence to personalized, risk-adapted frontline treatment plans and to monitor and manage emerging toxicities associated with novel combination regimens.

Speakers:

Rahul Banerjee, MD

Jesús G. Berdeja, MD

Krina K. Patel I

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care

This program is supported by Syndax Pharmaceuticals.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Great Hall AD

This activity employs a Medical Crossfire® format, a signature debate-style educational design that pairs short, focused didactic presentations with dynamic, moderated panel discussions. The program brings together four clinical experts to review the latest data regarding the management of patients with AML. These recorded questions are incorporated throughout the activity to address real-world challenges, uncertainties, and decision points encountered in routine care. Following each didactic segment, faculty engage in moderated panel discussions that respond directly to these clinical questions, providing expert interpretation and context while encouraging dynamic exchange. This approach ensures that the educational content remains grounded in the lived experiences of community oncologists, promotes bidirectional learning, and enhances the relevance and applicability of emerging data in AML management.

Chair:

Naval Daver, MD
MD Anderson Cancer Center
Houston, TX,  United States

Speakers:

Gail J Roboz, MD
Weill Cornell Medicine
New York,  NY, United States

Amer M. Zeidan, MD, MBBS
Yale Cancer Center
Connecticut,  United States

Managing Company Contact

Kelly McGregor
Email: [email protected]

---

Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum

This program is supported by AstraZeneca Pharmaceuticals, ADC Therapeutics America, Inc.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - La Nouvelle C

The treatment of diffuse large B-cell lymphoma is shifting rapidly from a single chemoimmunotherapy backbone toward a more biology-informed, mechanism-driven model of care. Routine integration of immunohistochemistry, gene expression profiling, and next-generation sequencing has redefined how clinicians classify disease, estimate prognosis, and select frontline therapy. Newly approved and emerging frontline regimens — including polatuzumab vedotin-based chemoimmunotherapy, Bruton tyrosine kinase inhibitor combinations, bispecific antibodies, and CAR T-cell strategies — expand options across germinal center, activated B-cell, and high-risk genomic subtypes. This session uses a debate-style design that pairs focused didactic content with moderated panel discussions, allowing expert clinicians to examine evolving evidence on molecular testing, frontline regimen selection, and treatment sequencing across the disease continuum.

Speakers:

Laurie Sehn, MD
BC Cancer Centre for Lymphoid Cancer
Vancouver,  BC, Canada

Catherine Thieblemont, MD
Hôpital Saint-Louis, AP-HP
Paris,  France

Jason Westin, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Realigning Modern Care Against MCL: Guidance on the Next Wave of Advances With BTKi Options, New Targeted Strategies, and Immunotherapy

This program is supported by an independent educational grant from AstraZeneca and BeOne Medicines.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Hilton - Grand Ballroom A

Guided by the insights of three (3) experts in mantle cell lymphoma (MCL), this initiative will combine the teaching power of real-world cases with the latest scientific evidence to enhance clinical decision-making across disease settings. Faculty will clarify the evidence supporting covalent BTK inhibitor (cBTKi)-based combinations, including both chemotherapy-inclusive and chemotherapy-free strategies, while also interpreting data on sequencing approaches involving non-covalent BTK inhibitors (ncBTKi) , new BCL2 inhibitors, and CAR-T therapy in MCL. In addition, the program will explore the integration of targeted and immunotherapy options across frontline and relapsed settings, including for ASCT-eligible, non-ASCT, and high-risk patients.

Chair:

Martin Dreyling, MD, PhD
LMU University Hospital
Munich,  Germany

Speakers:

Kami Maddocks, MD
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Christine Ryan, MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera

This program is supported by PharmaEssentia.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - R06-R09

Polycythemia vera and essential thrombocythemia are chronic myeloproliferative neoplasms driven by constitutive JAK/STAT pathway activation. These diseases carry significant thrombotic risk, burdensome disease-related symptoms, and the potential for progression to myelofibrosis or acute leukemia. Recent therapeutic advances — including the 2024 FDA approval of ropeginterferon alfa-2b for polycythemia vera, the phase 3 VERIFY readout of rusfertide in phlebotomy-dependent polycythemia vera, the SURPASS-ET superiority data for ropeginterferon alfa-2b versus anagrelide in essential thrombocythemia, and emerging activity from LSD1 inhibitors and other novel agents — have meaningfully expanded the treatment armamentarium and complicated treatment selection. This Cases and Conversations satellite symposium uses sequential patient cases and moderated faculty panel discussions to examine current and emerging treatment strategies across risk-stratified polycythemia vera and essential thrombocythemia, with focused attention on hydroxyurea resistance and intolerance, interferon-based therapy, JAK inhibitor positioning, and the management of treatment-related adverse events that affect long-term adherence and outcomes.

Chair:

Marina Kremyanskaya, MD, PhD
Icahn School of Medicine at Mount Sinai
New York,  NY, United States

Speaker:

Francesca Palandri, MD, PhD

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care

This program is supported by an independent educational grant from Bristol Myers Squibb.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 217-219

The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care is a 90-minute, case-based satellite symposium designed to address critical gaps in clinician readiness to integrate cereblon E3 ligase modulators (CELMoDs) into the management of relapsed/refractory multiple myeloma (RRMM). The program will be delivered at ASH 2026 with live and virtual participation and is structured to emphasize clinical decision-making in real-world practice settings.

The symposium features an interactive “Dueling Clinicians – Decision-IQ” format, in which a community hematologist-oncologist and an academic myeloma specialist independently evaluate evolving patient cases presented in stages. Guided by a moderator, faculty will discuss key decision points, including treatment sequencing in lenalidomide-refractory disease, selection among CELMoDs, CAR T-cell therapy, and bispecific antibodies, and management of treatment-related toxicities such as neutropenia. Real-time audience polling will be incorporated to assess practice patterns and reinforce learning.

Additional content will address the mechanistic differentiation of CELMoDs from IMiDs, emerging clinical data, combination strategies with T-cell–redirecting therapies, and the application of measurable residual disease (MRD) assessment in treatment planning. The activity is designed to provide clinicians with practical, evidence-based frameworks to support informed treatment selection, optimize patient management, and improve outcomes in RRMM.

Chair:

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

James Richard Berenson, MD

Luciano Jose Costa, MD, PhD

Managing Company Contact

Andrea Mathis , Global Learning Collaborative
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice

This program is supported by Sanofi

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Hall B2

This 90-minute expert panel discussion is designed to address evolving clinical challenges in the frontline management of NDMM. Faculty will contextualize recent clinical evidence within the current therapeutic landscape, focusing on the selection between intensive and modified regimens while evaluating the impact of quality-of-life and practical administration considerations on personalized care in the community setting. 

Chair:

Ola Landgren, MD, PhD
University of Miami
Miami,  FL, United States

Speakers:

Sikander Ailawadhi, MD
Mayo Clinic Comprehensive Cancer Center
Jacksonville,  FL, United States

Noopur Raje, MD
Mass General Brigham
Boston,  MA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going - A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by GSK, Bristol Myers Squibb

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Sheraton - Napoleon Ballroom CD

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on myelofibrosis (MF). Five clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, each faculty member will provide a number of interesting cases of patients with MF for program development. RTP will select specific deidentified patients for discussion during the activity consistent with the defined educational objectives. To set the stage for discussion and debate, at the beginning of each of the 5 modules, one of the faculty members will present a case from his/her practice. Each case discussion will attempt to frame a handful of educational issues and allow the faculty to describe how they currently think through the treatment and management of patients with MF. Following the case-based discussion, a faculty member will deliver a presentation reviewing relevant scientific knowledge, available data sets and ongoing research studies related to the topics under review. Audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Lucia Masarova, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Charlotte,  NC, United States

Francesco Passamonti, MD
University of Milan
Milan,  Italy

Raajit K. Rampal, MD, PhD

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by GSK

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Sheraton - Napoleon Ballroom AB

Presented by Neil Love and  Research To Practice, this 1.5-hour CME-accredited activity — offered to both in-person and virtual attendees — has been designed to address key questions regarding the use of bispecific antibodies and antibody-drug conjugates for patients with multiple myeloma (MM). Three clinical investigators will serve as the faculty, one of whom will moderate. Prior to the symposium, RTP will recruit 50 general medical oncologists/hematologists (GMOs) to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the use of bispecific antibodies and antibody-drug conjugates in MM. During the symposium, survey results highlighting areas of greatest interest will be presented. Each faculty member will then review relevant research findings, discuss current management approaches and provide perspectives on ongoing studies relevant to the topics prioritized by the GMOs who completed the survey. To promote audience engagement, attendees will be invited to submit questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Meletios Athanasios Dimopoulos, MD
National and Kapodistrian University of Athens
Athens,  Greece

Suzanne Trudel, MD
National and Kapodistrian University of Athens
Athens,  Greece

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms

This program is supported by GSK, PharmaEssentia, and Geron Corporation.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - R06-R09

The therapeutic landscape of myeloproliferative neoplasms has evolved rapidly, with new JAK inhibitors, novel targeted agents, and disease-modifying strategies reshaping how clinicians manage myelofibrosis, polycythemia vera, and essential thrombocythemia. Recent pivotal trial readouts for hepcidin mimetics, BET inhibitors, MDM2 inhibitors, LSD1 inhibitors, telomerase inhibitors, calreticulin-targeted antibodies, and novel interferons have expanded options while complicating risk stratification, sequencing, and toxicity management. This satellite symposium employs an interactive, case-based educational design that integrates didactic data summaries with moderated faculty panel discussions of complex patient scenarios across the MPN continuum. Four expert clinicians will examine emerging evidence, surface real-world decision points, and articulate practical perspectives on therapy selection in myelofibrosis, treatment intensification in polycythemia vera, and risk-adapted management of essential thrombocythemia. The format emphasizes peer exchange, audience response–driven discussion, and integration of evolving evidence into routine practice. Attendees will leave better prepared to apply guideline-aligned risk stratification, evaluate emerging clinical trial data across lines of therapy, and proactively monitor and manage treatment-related adverse events associated with both established and novel agents in MPN care.

Speakers:

Gabriela Soriano Hobbs, MD
Massachusetts General Hospital
Boston,  MA, United States

John O. Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
New York,  NY, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life

This program is supported by Novartis Pharmaceuticals Corporation

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Hall B2

Developed in partnership with the H Jean Khoury Cure CML Consortium, this interactive ninety-minute symposium addresses the evolving management of chronic myeloid leukemia. The purpose of the session is to bridge the gap between emerging clinical data and the practical needs of long-term survivorship. The theme centers on optimizing therapy selection and molecular monitoring while prioritizing patient quality of life and evidence-based care. A significant emphasis is placed on a patient-centric approach, utilizing shared decision-making to align therapeutic goals with individual preferences. The program is designed to maximize audience participation through real-time polling and a dedicated live question-and-answer opportunity, providing a direct forum to resolve specific clinical challenges with expert faculty. Discussions focus on navigating resistance, strategic sequencing, and the use of dose optimization to mitigate chronic toxicities. Ultimately, the session seeks to empower the healthcare team with the competence to improve treatment adherence and maximize the potential for treatment-free remission through a dynamic and highly interactive presentation. 

Chair:

Kendra L. Sweet, MD
Moffitt Cancer Center
Tampa,  FL, United States

Speakers:

Ehab Atallah I, MD
Medical College of Wisconsin
Milwaukee,  WI, United States

Michael Mauro, MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation. This activity is provided by PRIME Education. There is no fee to participate.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - R02-R05

As CAR T-cell therapy becomes increasingly integrated into the management of relapsed/refractory NHL, clinicians face growing challenges related to patient selection, referral timing, treatment sequencing, toxicity management, and care coordination across practice settings. Join this case-based, implementation-focused program designed to help clinicians apply the latest CAR T-cell evidence across the entire NHL care continuum. Through real-time polling, clinical decision checkpoints, multidisciplinary discussion, and faculty-guided case applications, alongside a real-world patient vignette sharing insights from the CAR T-cell experience,  attendees will learn how to identify appropriate patients earlier, optimize referral timing, navigate sequencing decisions, implement evidence-based bridging strategies, and manage CRS and ICANS with greater confidence.

Distinct from traditional didactic sessions, this symposium emphasizes actionable workflow solutions and coordinated care models that participants can immediately integrate into practice. Faculty will introduce the NHL CAR T-Cell Navigator, a practical point-of-care resource developed to support referral readiness, toxicity management, shared-care coordination, patient education, and operational consistency across practice settings. Don’t miss your opportunity to gain practical tools, evidence-based strategies, and real-world insights to improve CAR T-cell delivery, streamline multidisciplinary care, and expand access for patients with R/R DLBCL and FL.

Chair:

Peter Riedell, MD
University of Chicago
Chicago,  IL, United States

Speakers:

Daniel J Landsburg, MD
University of Pennsylvania
Philadelphia,  PA, United States

Shelby Sullivan, PharmD
PRIME Education, LLC
New York,  NY, United States

Managing Company Contact

Eryn Litvinas , PRIME Education, LLC
Email: [email protected]

---

FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With Modern BTKi as New STandards of Care for Frontline Treatment

This program is supported by an independent educational grant from AstraZeneca.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Hilton - Grand Ballroom CD

In collaboration with the HealthTree Foundation for CLL, this activity will emulate the interactive environment of a town hall meeting to deliver a curated, engagement-focused educational experience. Each “TownHall” segment will incorporate pre-submitted and live learner questions to drive dynamic Q&A discussions, realistic case scenarios, and focused expert presentations. Key topics will include the evidence and guidelines supporting time-limited BTK-BCL2 inhibitor combinations, with an emphasis on choosing effective, tolerable regimens; strategies for capturing prognostic, disease, and patient-specific factors that inform treatment planning and the selection of modern targeted therapies; and practical considerations in CLL care related to finite targeted treatment approaches, including logistical, dosing, and safety management challenges.

Chair:

Matthew S Davids, MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

Nicole Lamanna, MD
New York-Presbyterian/Columbia University Medical Center
New York,  NY, United States

Lydia Scarfo, MD
Università Vita-Salute San Raffaele
Milan,  Italy

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Hemophilia at the Crossroads: New Evidence for Individualized Care

This program is supported by Sanofi

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Great Hall BC

This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia.

Chair:

Steven Pipe, MD
University of Michigan
Ann Arbor,  MI, United States

Speakers:

Maissaa Janbain, MD
Louisiana Center for Bleeding and Clotting Disorders
New Orleans,  LA, United States

Allison P. Wheeler, MD
Washington Center for Bleeding Disorders
Seattle,  WA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care

This program is supported by Sanofi

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 217-219

Your patients with immune thrombocytopenia purpura (ITP)  deserve precision care — and this is where the conversation happens. This live symposium leverages real-world case studies and the latest advances in ITP pathophysiology to help you personalize treatment for even your most challenging patients, whether newly diagnosed, refractory, elderly, or at elevated thrombotic risk. You'll explore new and emerging therapies, unpack the key pathophysiology driving smarter treatment selection, and walk away with actionable frameworks to optimize patient outcomes.

ITP is so much more than a platelet count. We'll go beyond the numbers to address the full disease burden — including fatigue, cognitive impairment, heavy menstrual bleeding, and health-related quality of life — and show you how to integrate these critical considerations into shared decision-making with your patients and care team.

Join colleagues for an engaging, case-based experience designed to close knowledge gaps and elevate your practice. Come ready to think, discuss, and leave better equipped to champion the patients who need it most.

Chair:

Sandhya Panch, MD
Fred Hutchinson Cancer Center
Seattle,  WA, United States

Speakers:

Hanny Al-Samkari, MD
Harvard Medical School
Boston,  MA, United States

Gerald A Soff, MD
University of Miamo Health System
Miami,  FL, United States

Managing Company Contact

George Vuturo , AffinityCE
Email: [email protected]

---

Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors

This program is supported by Kura Oncology

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 393-396

Menin inhibition has rapidly evolved from a preclinical hypothesis to an FDA-approved therapeutic class with activity in molecularly defined subsets of acute myeloid leukemia. Two agents are now approved for relapsed/refractory disease in patients with NPM1 mutations or KMT2A rearrangements, with multiple combination regimens advancing in the relapsed/refractory and frontline settings. Yet the speed of development has outpaced clinical experience, leaving open questions on patient selection, treatment sequencing, response assessment, resistance, and proactive management of class-specific toxicities including differentiation syndrome and QTc prolongation. This satellite symposium uses a gamified hot seat design that places four expert clinicians in real time on case-based decision points, with audience polling on both the preferred treatment approach and the faculty member best positioned to defend it. Brief didactic segments anchor the latest efficacy and safety data for approved and investigational menin inhibitors, including monotherapy and combination strategies with venetoclax, hypomethylating agents, intensive induction backbones, and FLT3 inhibitors. Attendees will leave better prepared to identify candidates for menin inhibitor therapy, integrate emerging combination data into individualized care plans, anticipate and mitigate class-specific toxicities, and recognize early signals of resistance.

Chair:

Eunice Sue Wang, MD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies

This program is supported by Deciphera Pharmaceuticals, Inc

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - La Nouvelle C

Primary central nervous system lymphoma is a rare and aggressive extranodal lymphoma confined to the brain, leptomeninges, spinal cord, and eyes, with persistent heterogeneity in frontline management, evolving molecular insights, and a rapidly expanding portfolio of targeted agents for relapsed and refractory disease. High-dose methotrexate–based induction, consolidation choices between autologous stem cell transplant and whole-brain radiotherapy, and integration of MYD88/CD79B-directed and IRAK4-directed strategies have introduced new clinical decision points that often outpace routine practice. This satellite symposium employs a case-based tumor board design that pairs concise didactic framing with moderated faculty discussion across three realistic clinical scenarios, allowing four expert clinicians to examine evolving evidence and articulate differing perspectives on induction optimization, molecular interpretation, and sequencing of emerging targeted therapies. Attendees will leave better prepared to apply evidence-based induction and consolidation strategies, interpret PCNSL-specific molecular alterations and pharmacology, and integrate emerging targeted agents with proactive toxicity monitoring across the disease continuum.

Chair:

Kathryn Tringale, MD, MAS
UC San Diego School of Medicine
San Diego,  CA, United States

Speaker:

Lisa M. DeAngelis, MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

MDS in the Modern Era: Getting Ahead of the 8-Ball

This program is supported by Bristol Myers Squibb, Geron, and OrcaBio

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Hall C

This 90-minute symposium explores the management of myelodysplastic syndromes (MDS) across the disease continuum, focusing on evidence-based strategies for both lower- and higher-risk disease. The session provides a framework for transitioning from an outdated paradigm of reactive transfusion support to a model of proactive early intervention with disease-modifying therapies. Faculty will begin with a review of how molecular biomarkers and advanced prognostic scoring systems inform diagnostic classification and guide therapy selection for patients with heavy transfusion burdens. For lower-risk MDS, the program reviews strategies to achieve durable transfusion independence and improve survival outcomes by addressing underlying disease biology earlier in the treatment course. For patients with higher-risk disease, the discussion covers the selection and sequencing of hypomethylating agents, a comparison of oral vs intravenous formulations, and the role of targeted therapies in refractory settings. The session then explores recent progress in the allogeneic transplant pathway, emphasizing the importance of early referral and the role of precision-engineered graft options for expanding eligibility and improving outcomes in older and frailer populations. Through case-based discussion, the faculty addresses the coordination of care and the management of treatment-emergent toxicities to maintain adherence. The session concludes with a review of forthcoming clinical data to help clinicians integrate recent evidence into individualized management plans. 

Chair:

Guillermo Garcia-Manero, MD
University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Caspian Oliai, MD
University of California Los Angeles
Los Angeles,  CA, United States

David Sallman, MD
Moffitt Cancer Center
Tampa,  FL, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era

This program is supported by Jazz Pharmaceuticals, Inc., and Amgen, Inc.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - La Nouvelle A-B

The therapeutic landscape of acute lymphoblastic leukemia has been transformed by bispecific T-cell engagers, antibody-drug conjugates, CAR T-cell therapies, next-generation tyrosine kinase inhibitors, menin inhibitors, and recombinant asparaginase formulations. These advances have improved outcomes across Ph-positive, Ph-negative, pediatric, adolescent and young adult, and older adult populations, while complicating decisions around induction, consolidation, and salvage sequencing. The growing role of high-sensitivity measurable residual disease testing adds further nuance. This session employs a debate-style design that pairs concise didactic content with moderated panel discussions, allowing experts to examine evolving evidence and articulate differing perspectives on frontline therapy, salvage sequencing, CAR T-cell deployment, asparaginase management, and MRD-directed care. Attendees will be better prepared to apply guideline-aligned strategies and to anticipate and manage treatment-related toxicities.

Chair:

Hagop Kantarjian I, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Aaron C. Logan, MD, PhD, MPhil
University of California, San Francisco (UCSF)
San Francisco,  CA, United States

Claire Roddie, MBChB, PhD
University College London (UCL Cancer Institute)
London,  United Kingdom

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice

This program is supported by AstraZeneca, Johnson and Johnson, and Sanofi Genzyme. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 243-245

Join Decera Clinical Education and NCCN for an interactive symposium focused on applying updated evidence and guideline-based strategies to multiple myeloma management across the disease continuum. This program will examine practical decision points from smoldering myeloma and newly diagnosed disease through first relapse and heavily pretreated relapsed/refractory multiple myeloma. Through case challenges, rapid-fire knowledge checks, expert discussion, and audience-driven questions, the session will translate evolving clinical data into individualized treatment approaches that account for disease risk, cytogenetics, transplant eligibility, age, fitness, comorbidities, prior therapy, patient preferences, and access considerations. Key themes include risk stratification and treatment initiation in smoldering myeloma, selection of triplet and quadruplet regimens in newly diagnosed disease, use of measurable residual disease and maintenance strategies, sequencing of novel therapies at relapse, and integration of CAR T-cell therapy, bispecific antibodies, antibody–drug conjugates, CELMoDs, SINE inhibitors, and subcutaneous formulations. The overall purpose is to strengthen equitable, patient-centered, evidence-based care while addressing real-world barriers to optimal treatment, toxicity management, clinical trial access, and guideline implementation.

Chair:

Carol Huff, MD
Johns Hopkins University
Baltimore,  MD, United States

Speaker:

Larry D Anderson Jr, MD, PhD
UT Southwestern Medical Center
Dallas,  TX, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions

This program is supported by AstraZeneca and Genmab. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 265-268

Join Decera Clinical Education for an interactive symposium examining how bispecific antibody–based therapies are reshaping treatment for follicular lymphoma and diffuse large B-cell lymphoma. This program will explore clinically meaningful differences among established and emerging bispecific antibodies, including mechanisms of action, structural characteristics, dosing considerations, safety profiles, and implications for individualized treatment sequencing. Through concise evidence updates, rapid-insights polling, interactive cases, and real-world community challenges, the session will translate recent and emerging data into practical strategies for selecting appropriate patients, integrating bispecific antibody–based regimens across the disease course, and identifying candidates for clinical trials. Key themes include optimizing therapy in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, anticipating how evolving evidence may change future treatment algorithms, and addressing operational considerations such as step-up dosing, outpatient vs inpatient administration, adverse event monitoring, CRS and neurotoxicity management, infection risk, patient education, and care coordination. The overall purpose is to equip clinicians to confidently and safely incorporate bispecific antibody–based therapies into lymphoma care across community and specialist settings.

Chair:

Matthew Matasar, MD, MS
Rutgers Cancer Institute
New Brunswick,  NJ, United States

Speaker:

Tycel Phillips, MD
Rutgers Cancer Institute
New Brunswick,  NJ, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence

This program is supported by an educational grant from Sanofi.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 208-210

Anti-CD38–based quadruplet regimens are rapidly reshaping frontline treatment for newly diagnosed multiple myeloma (NDMM). In this interactive 60-minute symposium, two leading multiple myeloma experts will explore how to turn these evolving updates—alongside advances in minimal residual disease (MRD) testing, transplant criteria, and treatment delivery—into practical, personalized treatment strategies.  Through real-world insights and expert discussion, they will examine how to move beyond a “one-size-fits-all” approach to optimize frontline patient care in everyday practice. 

Get up to speed on the rapidly changing NDMM treatment landscape and leave with practical insights you can apply immediately in clinical practice.

 Don’t miss the live Q&A, where faculty will address real-world questions and help refine your approach to NDMM management.

Speakers:

Amrita Krishnan, MD
Judy and Bernard Briskin Center for Multiple Myeloma
City of Hope,  United States

Adriana Rossi, MD, MSc

Managing Company Contact

Kaitlyn Bell , No affiliations
Email: [email protected]

---

The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-line to Frontline Care

This program is supported by independent educational grants from AstraZeneca and Regeneron.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Hilton - Grand Ballroom A

PeerView’s “MasterClass & Case Forum” will combine concise, evidence-based instruction with real-world case discussions to help hematology-oncology clinicians develop practical skills for integrating bispecific antibodies into the management of non-Hodgkin lymphoma (NHL). Through expert-led presentations and interactive case debates, the activity will explore evidence and guidelines supporting bispecific antibody monotherapy and combination strategies, including principles for treatment selection and sequencing. Faculty will also address considerations surrounding newer dosing formulations and administration approaches, as well as best practices for the prevention and management of key toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections. This program will also prepare learners for emerging and next-generation bispecific antibody platforms, including newer CD20×CD3 and CD19×CD3 therapies, and discuss their  impact on future NHL care.

Chair:

Max Topp, MD
Universitätsklinikum Würzburg
Würzburg,  Germany

Speaker:

Sameh Gaballa, MD
H. Lee Moffitt Cancer Center
Tampa,  FL, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms

This program is supported by educational grants from Caribou Biosciences, Inc., Kite, A Gilead Company, Legend Biotech, and Miltenyi Biomedicine. <span>This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma</span>

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
Hilton - Grand Ballroom AB

CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy represents a standard of care immunotherapy option across non-Hodgkin lymphoma (NHL), including in diffuse large B-cell and follicular lymphoma. Advances in manufacturing platforms and the development of next-generation constructs promise to provide additional options—including dual targeting, faster manufacturing, or in-vivo CAR-Ts that hold potential to expand access for patients who may not be able to undergo the complex delivery of traditional cell therapies. Collectively these developments are expanding the therapeutic footprint of CAR-T and accelerating the integration of cellular therapy in modern NHL management protocols.

PeerView has partnered with HealthTree Foundation for Non-Hodgkin Lymphoma to prepare this educational symposium featuring a panel of hematology-oncology experts. During this event, the faculty will use workshop-style discussions to offer practical guidance for operationalizing CAR-T within multidisciplinary workflows and care pathways while addressing the movement of CAR-T earlier in the treatment continuum and the emergence of potential next-generation cellular therapy options.

Chair:

Sairah Ahmed, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Sunita Dwivedy Nasta, MD

Nirav N. Shah, MD
Medical College of Wisconsin
Milwaukee,  WI, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know:  A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
Sheraton - Napoleon Ballroom AB

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — has been designed to address many of the questions related to the use of novel agents for patients with non-Hodgkin lymphoma (NHL) for which learners want and need answers. Five clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, RTP will recruit 50 general medical oncologists/hematologists (GMOs) to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the use of novel agents in NHL. During the symposium, selected survey results highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss their current management approaches and provide perspectives on ongoing studies relevant to the topics prioritized by the GMOs who completed the survey. To promote audience engagement, in-person and virtual attendees will be able to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Paolo Fabrizio Caimi, MD, MBA
University Hospitals Seidman Cancer Center
Cleveland,  OH, United States

Mark Hoffman, MD
The University of Kansas Cancer Center
Kansas City,  MO, United States

Brad S Kahl, MD
Washington University School of Medicine
St Louis,  United States

Sonali Smith, MD

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care

This program is supported by F. Hoffmann-La Roche Ltd

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - Great Hall BC

This 90-minute symposium features a global expert panel addressing the 2026 regulatory landscape for bispecific antibodies in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). The purpose is to translate clinical evidence into practical strategies, with a focus on second-line setting. The theme centers on the strategic selection and sequencing of therapies, evaluating the criteria for selecting between bispecific antibodies and other novel therapies based on disease urgency, frailty, and geographic access. 

The program will also integrate essential considerations for community practice, including established protocols for managing treatment related toxicities. Faculty highlight the importance of standardizing academic-to-community patient handoffs and provide strategies for long-term infection surveillance. Furthermore, the session explores the therapeutic horizon, including frontline updates and relevant abstracts from the upcoming ASH 2026 meeting. Through interactive discussion and a live question-and-answer segment, this symposium equips the healthcare team with actionable takeaways to improve safety, optimize treatment delivery, and ensure access to these novel therapies across various care environments. 

Chair:

Wendy Osborne, MRCP, MRCPath
Newcastle Hospitals
Newcastle,  United Kingdom

Speakers:

Haifaa Abdulhaq, MD
University of California, San Francisco
Fresno,  CA, United States

Michael Dickinson, MD, MBBS, FRACP, FRCPA
Peter MacCallum Cancer Center
Melbourne,  Australia

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Cases and Conversations™: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant

This program is supported by Omeros Corporation and Gamida Cell.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - La Nouvelle C

Allogeneic hematopoietic cell transplantation remains the only curative therapy for many patients with high-risk hematologic malignancies and severe non-malignant hematologic disorders, yet two of the highest-impact clinical decisions in the transplant pathway have been fundamentally reshaped within the past 12 months. The December 2025 approval of a nicotinamide-expanded cord blood platform for severe aplastic anemia, following its 2023 approval in hematologic malignancies, has expanded the donor hierarchy into non-malignant disease. The approval of narsoplimab, a first-in-class MASP-2 inhibitor for transplant-associated thrombotic microangiopathy, has introduced on-label therapy into a clinical space previously defined entirely by off-label management. This Cases and Conversations satellite symposium uses sequential patient cases and moderated faculty panel discussions to examine graft platform selection across malignant and non-malignant indications and the recognition, risk stratification, and mechanism-directed management of transplant-associated thrombotic microangiopathy across the post-transplant continuum.

Chair:

Robert J Soiffer, MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

Jeffrey Laurence, MD

Alessandro Rambaldi, MD

Michelle L. Schoettler, MD
Emory University School of Medicine
Atlanta,  GA, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis

This program is supported by Blueprint Medicines, a Sanofi company and Cogent Biosciences, Inc.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - Hall C

Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis, is a 90-minute live CME/CE symposium with livestreaming and social media simulcast. Attendees will have an opportunity to explore clinical turning points to address inertia and uncertainty to optimize treatment decisions, particularly when considering escalation to disease-directed therapy.  

Chair:

Tracy I George, MD
University of Utah
Salt Lake City,  UT, United States

Speakers:

Hussein Ali Abbas, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Lindsay Rein, MD
Duke University Health System
Durham,  NC, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Medical Crossfire®: Frontline Decision-Making in CLL — Today's Choices, Tomorrow's Consequences

This program is supported by Eli Lilly and Company.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - La Nouvelle A-B

The frontline therapeutic landscape for chronic lymphocytic leukemia has shifted decisively from chemoimmunotherapy toward targeted oral agents, and clinicians now choose among continuous covalent and non-covalent BTK inhibitors, fixed-duration BCL-2 inhibitor combinations, and emerging MRD-guided strategies. Pivotal phase 3 readouts — AMPLIFY (acalabrutinib + venetoclax ± obinutuzumab), CLL17, BRUIN CLL-313/-314 (pirtobrutinib), CELESTIAL-TN (sonrotoclax + zanubrutinib), and MAJIC — have reshaped both the treatment armamentarium and the decision framework around fixed-duration vs continuous therapy. Real-world data show persistent gaps in molecular testing, treatment selection, and toxicity management. This Medical Crossfire® session uses focused didactic primers paired with moderated expert debate to examine the frontline decision points clinicians face every day, with attention to molecular testing, fixed-duration vs continuous therapy, MRD-guided approaches, and proactive AE management.

Chair:

Jennifer R. Brown, MD, PhD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

Arnon Philip Kater, MD, PhD
Amsterdam UMC, University of Amsterdam
Amsterdam,  Netherlands

Carsten Utoft Niemann, MD, PhD
Rigshospitalet, Copenhagen University Hospital
Copenhagen,  Denmark

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia

This program is supported by Servier Pharmaceuticals, LLC.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - 343-345

This symposium will address critical gaps in knowledge, competence, and clinical application among hem/onc clinicians managing patients with acute lymphoblastic leukemia, particularly adolescents and young adults. The activity is designed to support alignment with evolving evidence and guideline recommendations, with the ultimate goal of optimizing patient outcomes. The live symposium will employ an expert roundtable educational format in which a faculty panel will present evidence-based content, engage in interactive discussions, and provide practice insights to contextualize complex and data-rich information. Emphasis will be placed on real-world decision-making to help learners navigate the unique clinical and psychosocial considerations involved in treating this population. Embedded audience polling questions throughout the program will promote active engagement, reinforce clinical reasoning, and facilitate practical application of evidence-based strategies in patient care.

Chair:

Stephen P. Hunger, MD

Speakers:

Seth E Karol, MD

Marlise Rachael Luskin, MD

Managing Company Contact

Greg Maheu
Email: [email protected]

---